Skip to content
Calculator

Grey-Market Encyclopedia · Legal risks

Legal risks of grey-market peptides

Who the law applies to, and what it says: FDA's view of unapproved peptides, what a 'research use only' label does in law, what happens at the border, the anti-doping rules for athletes, and how three other countries treat the same products. Quoted from regulators, with their dates. Not legal advice.

Last updated October 28, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Every claim sourced · No products sold, no seller named

📋 Key takeaways

In the US, a peptide sold for people to take is a drug, and one without FDA approval is an unapproved drug. FDA has warned companies that sold such drugs "falsely labeled 'for research purposes' or 'not for human consumption'".1

A 'research use only' label describes a use; it does not create one. What a product is for is judged by the seller's objective intent, shown by its claims, advertising and the circumstances of the sale.2 Regulators in Canada, Australia and the UK say the same label does not make supply lawful.111213

For buyers, FDA says that "in most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use"; its personal importation policy is discretion in narrow cases, not a right.4 As of March 2026, refused drugs worth $2,500 or less can be destroyed.6

On this page

  1. FDA status: unapproved drugs
  2. What 'research use only' labelling does, and does not do
  3. Personal importation and customs
  4. Who enforcement is aimed at
  5. State boards and clinics
  6. Athletes: WADA
  7. How this varies by country
  8. Frequently asked questions
  9. Related on Grey Peptides
  10. Sources

FDA status: unapproved drugs

A peptide marketed for people to take is a drug under US law, and a new drug may be sold only with FDA approval (our summary; the encyclopedia marks each compound's status on its entry). Most peptides sold on the grey market have no approval anywhere, and some are investigational drugs still in trials; the maker of retatrutide, for example, says no medicine containing it has been approved for human use by any regulator.14 Copies of approved drugs are unapproved too when they come from someone other than the approved manufacturer: FDA's page on unapproved GLP-1 drugs warns about such products, including those sold "for research purposes".1

Compounding is a separate, lawful route with its own limits. A state-licensed pharmacy or physician may compound under section 503A on a patient-specific prescription, and an FDA-registered outsourcing facility under section 503B; compounded drugs are not FDA-approved, but they are made under those rules.3 Whether a given peptide may be compounded depends on FDA's bulk substance lists, which our regulatory tracker follows.

What 'research use only' labelling does, and does not do

Research-use labels exist for a real purpose. A new drug shipped for laboratory research on animals or in vitro tests must carry a caution that it is for investigational use only in laboratory research animals or for tests in vitro, and is not for use in humans; the shipper must use due diligence to make sure the consignee actually runs such tests, and keep records of each shipment for two years.5 Used that way, the label marks a legitimate shipment to a laboratory.

What it does not do is change what a product is when it is sold to the public for people to use. Under FDA's regulation on intended use, a product's intended use is "the objective intent of the persons legally responsible for the labeling", which can be shown by their claims, advertising and statements, the design of the product, and the circumstances of its distribution, including when it is offered for a use for which it is neither labelled nor advertised.2 FDA says the products it has warned about were "sold directly to consumers for human use with dosing instructions" despite their research labels.1 Our research-use-only article goes through the warning letters and the federal prosecutions in which such labels were called a ruse.

Other regulators take the same view. Health Canada says "For Research Use Only" labelling "does not make these products legal or exempt from regulatory requirements".11 Australia's regulator says research-use disclaimers do not make supply lawful, do not change a product's regulatory status and do not permit importation.12 In the UK, the MHRA told a Scottish broadcaster in March 2026 that it disregards claims that products are for research purposes where they are used to avoid medicines regulation (news report).13

Personal importation and customs

FDA's page on personal importation, content current as of August 18, 2025, opens with the rule: "In most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use." It then lists situations in which FDA staff may use discretion. One is a product not for a serious condition with no known significant health risk. The other is a prescription drug for a serious condition where effective treatment may not be available in the US, the product is not promoted to US residents and poses no unreasonable risk, the person affirms in writing that it is for personal use, the quantity is generally no more than three months' supply, and the person gives a US-licensed doctor's details or shows that treatment began abroad. The page also says that a drug approved abroad but not in the US is illegal to import.4

The Congressional Research Service, in its March 10, 2026 brief, says current law "generally does not permit individuals to import or reimport prescription drugs for their own use", and that FDA's policy "has normally not been intended as a way for consumers to bring lower-priced prescription drugs into the United States" but to allow access to treatments not otherwise available here.7 A research peptide with no approval and no treating doctor meets few of those conditions (our reading of the two documents).

At the border, US Customs and Border Protection works with FDA: a 2023 CBP release on a seized shipment of foreign unapproved medications says "CBP works in conjunction with FDA to intercept illegal shipments like these".8 When FDA refuses a drug, it sends a Notice of FDA Action giving the reasons and an opportunity to respond, and for refused drugs valued at $2,500 or less it may destroy them without offering the option to export. FDA's page, current as of March 16, 2026, says the owner is legally responsible for storage and destruction costs but that it "generally does not intend to pursue recovery of storage and destruction costs against individual consumers".6 Our customs seizures article explains the notice step by step.

Who enforcement is aimed at

FDA's published actions in this market are aimed mainly at sellers: its GLP-1 page describes warnings to companies, not to buyers.1 For an individual importing a small quantity for personal use, the outcomes FDA's import pages describe are refusal and destruction of the product, with costs generally not pursued.6 That is a description of FDA's stated practice, not a promise: the law itself says personal importation is illegal in most circumstances,4 and selling, sharing or reselling what was imported is a different matter (our reasoning; we found no FDA page describing a safe harbour for either). Quantity matters too: FDA's discretion is described for personal use only, generally up to three months' supply.4

State boards and clinics

Pharmacies and pharmacists are licensed by the states, and compounding under section 503A is done by state-licensed pharmacies and physicians.39 State rules on who may prescribe, compound or administer a peptide, and on clinics such as medical spas, differ from state to state, so we do not summarise them here (our reasoning). A 2026 report for nurse practitioners describes patients turning to "research-grade" peptides bought online and to unregulated providers including medical spas, and the legal pitfalls of compounded copies.10 A buyer who wants a lawful route for an approved peptide can use a licensed clinician and a licensed pharmacy; our guide to legitimate prescriptions explains how to check both.

Athletes: WADA

For athletes in sport governed by the World Anti-Doping Code, the question is not only legal. The 2026 Prohibited List's section S0 bans at all times "any pharmacological substance" not addressed elsewhere on the List "and with no current approval by any governmental regulatory health authority for human therapeutic use", naming drugs under preclinical or clinical development and naming BPC-157 as an example.15 Other peptides fall under other sections of the List; our WADA hub lists them by compound. A label saying research use only does not change a substance's status on the List (our reasoning: the List defines substances, not labels).

How this varies by country

The detail differs by country; the direction is the same in the three below. Each has a fuller page in our peptide laws by country section.

  • Canada. Health Canada says peptides are generally regulated as prescription drugs, that "unauthorized drug products are illegal in Canada", that research-use labelling does not exempt them, and that it works with the Canada Border Services Agency to stop unauthorized shipments.11 See peptide laws in Canada.
  • Australia. The Therapeutic Goods Administration says unapproved peptide products may be imported under its personal importation scheme only if they meet all its conditions, including a medical authorisation or prescription where required and clear labelling of the active ingredient and strength, and that products failing them are not released: it will notify the Australian Border Force to seize and destroy them.1216 See peptide laws in Australia.
  • United Kingdom. The MHRA told STV News in March 2026 that it disregards research-purposes claims used to avoid medicines regulation and will take compliance action where a product is a medicine that is not appropriately authorised; it also said peptides sold without medicinal claims would not be considered medicines. The Department of Health and Social Care urged people to get medicines only from a regulated pharmacy (news report).13 See peptide laws in the UK.

Frequently asked questions

Is it illegal to buy research peptides in the US?

FDA says that in most circumstances it is illegal for individuals to import drugs into the US for personal use, and that its personal importation policy is discretion in narrow cases. Selling unapproved drugs for human use is what its warnings target.41

Does a 'research use only' label make a peptide legal?

No. Intended use is judged by the seller's objective intent, shown by claims, advertising and the circumstances of sale, and FDA, Health Canada and Australia's regulator all say the label does not make supply lawful.21112

What happens if customs stops my peptide order?

FDA sends a notice with a chance to respond. As of March 2026, refused drugs worth $2,500 or less can be destroyed without the option to export, and FDA generally does not pursue costs from individual consumers.6

Can athletes use grey-market peptides?

Some are banned at all times: WADA's S0 bans substances with no current approval for human therapeutic use, naming BPC-157.15

Grey market hub Buyer's guide: start here Physical risks Financial risks How buyers find sellers, and the scams The 2025 China crackdown Contamination and skin reactions US warehouses and domestic stock What 'research use only' means Chinese peptides explained Peptide raves and group buys Peptides on Amazon, Temu and TikTok Shop How to evaluate a peptide vendor Purity is not safety Grey-market glossary

Sources

Regulations, regulators' pages and the WADA List are quoted with the dates they show; news is labelled as news. All read October 28, 2026. This page describes the law; it is not legal advice.

  1. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026; read October 28, 2026. Source
  2. Code of Federal Regulations. 21 CFR 201.128, Meaning of 'intended uses' (as amended by the final rule of August 2, 2021, 86 FR 41383). Text read at the Legal Information Institute, October 28, 2026. Source
  3. U.S. Food and Drug Administration. Compounding Laws and Policies (sections 503A and 503B). Content current as of December 17, 2024; read October 28, 2026. Source
  4. U.S. Food and Drug Administration. Personal Importation. Content current as of August 18, 2025; read October 28, 2026. Source
  5. Code of Federal Regulations. 21 CFR 312.160, Drugs for investigational use in laboratory research animals or in vitro tests. Text read at the Legal Information Institute, October 28, 2026. Source
  6. U.S. Food and Drug Administration. Administrative Destruction Authority (Import Basics). Content current as of March 16, 2026; read October 28, 2026. Source
  7. Congressional Research Service. Prescription Drug Importation (In Focus IF11056), updated March 10, 2026. Read October 28, 2026. Source
  8. U.S. Customs and Border Protection. Milwaukee CBP intercepts shipment of prescription medication. Local media release, February 16, 2023; read October 28, 2026. Source
  9. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (503A: state-licensed pharmacies and physicians). Content current as of April 1, 2026; read October 28, 2026. Source
  10. Trainer N. The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions. J Am Assoc Nurse Pract. 2026. PMID 42201545. Source
  11. Health Canada. Think twice before injecting peptides bought online: unauthorized products can seriously harm your health. Public advisory, April 9, 2026; read October 28, 2026. Source
  12. Therapeutic Goods Administration (Australia). Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety alert, no date shown; read October 28, 2026. Source
  13. Flett A. The peptide boom: call for review of legal 'loophole' allowing unregulated injectables to be sold online. STV News, March 19, 2026 (updated March 20, 2026), with statements from the MHRA and the Department of Health and Social Care. News report; read October 28, 2026. Source
  14. Eli Lilly and Company. Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market. News release, August 12, 2026 (the manufacturer; Standing rule 3 (h)). Read October 28, 2026. Source
  15. World Anti-Doping Agency. The 2026 Prohibited List, in force January 1, 2026: S0, non-approved substances. Read October 28, 2026.
  16. Therapeutic Goods Administration (Australia). TGA warning on the risks of importing unapproved peptide products. Safety alert, no date shown; read October 28, 2026. Source

This page describes how the grey market works; it is not legal or medical advice, and it is not a guide to buying. Grey Peptides sells nothing, links to no seller and rates none. If you have taken a product and feel unwell, contact a clinician or Poison Help (1-800-222-1222 in the US).